Integra Lifesciences Holdings (IART) Accumulated Expenses (2009 - 2026)

Integra Lifesciences Holdings has reported Accumulated Expenses for 18 years, with the latest figure at $107.6 million in Q2 2026.

• Quarterly Accumulated Expenses fell 18.09% year-over-year to $107.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $107.6 million (down 18.09% YoY) and the FY2025 annual result came in at $130.5 million, up 7.04% from the prior year.
• Accumulated Expenses eased to $107.6 million in Q2 2026 per IART's latest filing, from $133.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $137.4 million in Q1 2025 and troughed at $79.0 million in Q3 2022.
• A 5-year average of $109.5 million and a median of $106.5 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses slumped 33.56% in 2022, then surged 46.1% in 2024.
• Over 5 years, Accumulated Expenses stood at $80.0 million in 2022, then advanced by 26.0% to $100.8 million in 2023, then climbed by 20.89% to $121.9 million in 2024, then grew by 7.04% to $130.5 million in 2025, then decreased by 17.53% to $107.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $107.6 million, $133.3 million, and $130.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.